On the 6th of September, Tuesday, the Drugs Controller General of India (DCGI) approved Bharat Biotech’s intranasal COVID-19 (Wuhan virus) vaccine for restricted emergency use.
Drugs Controller General of India (DCGI) V.G. Somani approved restricted emergency use of the vaccine iNCOVACC (BBV154) for primary two-dose schedule for people above 18 years of age. The vaccine was jointly developed by Covaxin-maker Bharat Biotech and Washington University St. Louis and is world’s first intranasal vaccine against the Wuhan Virus.
After the approval from the DCGI, Mr. Mansukh Mandaviya, the Union Health Minister took to Twitter and said, “Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in an emergency situation.”
In addition, the Hyderabad based pharma firm also released an official statement in this regard. Shared on Tuesday evening, the statement read, “Its iNCOVACC (BBV154), the world’s first intranasal COVID-19 vaccine, received approval from DCGI under restricted use in an emergency situation for ages 18 and above.”
Dr. Krishna Ella, the Chairman of the Bharat Biotech said, “Despite the lack of demand for covid-19 vaccines, we continued product development in intra-nasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases.”
Notably, the approval of the intranasal vaccine, iNCOVACC, came after its successful phase I, II and III clinical trials, and would boost India’s COVID-19 vaccination drive.
Mango News Link
Telegram: https://t.me/mangonewsofficial
Google Play Store: https://bit.ly/2R4cbgN
Apple / iOS Store: https://apple.co/2xEYFJ
Subscribe to our email newsletter to get the latest posts delivered right to your email.
Comments